Macrovascular disease prevention in T2DM: untangling the web

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1665, 2008-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus

By Johansen O.E.

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 4, 2003-01 ,pp. : 283-297

Adis International

Access to resources Recommend Favorite

Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus: Implications of the Results of Recent Clinical Trials in Type 2 Diabetes

By Tandon Nikhil

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 1, 2012-02 ,pp. : 7-22

Adis International

Access to resources Recommend Favorite

Current and Future Treatment Directions in T2DM

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Pioglitazone improves measures of T2DM and dyslipidaemia

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Thiazolidinediones considered in T2DM management update

Inpharma, Vol. 1, Iss. 1617, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite